The tumor suppressive role of KEAP1: Underlying mechanisms and therapeutic implications.

Abstract

Kelch-like ECH-associated protein 1 (KEAP1) serves as an adaptor protein for the Cullin3-RING E3 ubiquitin ligase complex, orchestrating the ubiquitination and subsequent degradation of its substrates including the transcription factor NF-E2-related factor 2 (NRF2) to regulate cell functions. Emerging evidence demonstrates that genetic alterations (mutations or functional inactivation) of KEAP1 occur frequently across multiple cancer types. KEAP1 aberrations lead to constitutive activation of its substrates, which in turn promotes tumorigenesis, confers therapeutic resistance, and facilitates immune evasion. In this review, we systematically summarize and discuss the molecular mechanisms underlying the tumor-suppressive function of KEAP1, the spectrum and functional consequences of cancer-associated KEAP1 mutations, the clinical implications of KEAP1 alterations as prognostic biomarkers, and potential therapeutic strategies targeting the KEAP1-NRF2 axis. Our work provides comprehensive insights into the multifaceted roles of KEAP1 in cancer biology and its therapeutic implications.

Key Findings

• KEAP1 functions as a tumor suppressor by regulating the degradation of NRF2 and other substrates.
• Genetic alterations in KEAP1 lead to constitutive activation of NRF2, promoting tumorigenesis, therapeutic resistance, and immune evasion.
• Targeting the KEAP1-NRF2 axis offers potential therapeutic strategies for cancer treatment.

Clinical Significance

Citation

Zhang Ziyu, Jin Xiangting, Chen Junhonget al.. The tumor suppressive role of KEAP1: Underlying mechanisms and therapeutic implications. Biochimica et biophysica acta. Molecular basis of disease. 2026-Apr-10.